Negative Prostate Biopsy Followed by a Cancer Diagnosis: Was Something Missed?

A negative prostate biopsy feels like a closed door. You waited through the appointment, the procedure, and the days before the call, and then you heard the words you were hoping for: no cancer found.

Months or years later, a second biopsy or a climbing PSA brings the diagnosis you were told you didn’t have. The first question is whether the doctor missed something. Sometimes the first biopsy simply couldn’t see the cancer.

This article explains how to tell those apart, what New York law requires you to prove, and why the deadline to act matters.

Can a Biopsy Be Negative When Cancer Is There?

Yes. A standard biopsy takes about 12 thin cores from a gland that holds far more tissue than the needle ever touches. Tumors are often small and scattered, and a needle can pass right beside one without collecting a single cancer cell. The front of the gland, the apex, and the transition zone are the hardest areas to sample.

Large trials have confirmed this limit. In the PRECISION trial, MRI-targeted biopsy found clinically significant cancer in 38% of men, compared with 26% for standard biopsy. A negative biopsy is one piece of information, not a final answer. What happens next is what counts. Our page on how prostate cancer is diagnosed explains how the cores are taken and graded.

Three Ways a Cancer Gets Missed After a Negative Biopsy

A later diagnosis tends to trace back to one of three situations:

1. The cancer wasn’t sampled. The biopsy was done properly and the needle simply missed the tumor. This is a known limitation of the test, and usually not negligence.

2. The follow-up failed. A doctor ignored a rising PSA, an abnormal exam, or a suspicious MRI, or never ordered the repeat testing the situation called for.

3. The pathology or the paperwork failed. Cancer was in the sample but misread, a warning finding on the report was ignored, or a result never reached the patient.

The second and third situations are where legal claims arise. The question is never just whether cancer was missed. It’s whether a reasonably careful physician would have caught it, and whether the delay made things worse.

What Should Have Happened After the Negative Biopsy

The American Urological Association and the National Comprehensive Cancer Network both describe continued follow-up when a biopsy is negative but suspicion remains. Which steps apply depends on your PSA trend, exam findings, and family history. The common options are:

• Repeat PSA testing to watch for a rising trend

• A prostate MRI to look for areas the first biopsy may have missed

• An MRI-targeted biopsy if a suspicious area appears

• Blood or urine biomarker tests that estimate cancer risk

• A repeat biopsy when concern continues

A negative result shouldn’t end the conversation when the reason for the biopsy hasn’t gone away. If your PSA kept climbing, an exam found something abnormal, or an MRI showed a lesion, a doctor who said “you’re fine, come back in a few years” may have departed from accepted practice.

Your urologist’s notes should show what was recommended and why. If they show nothing, that silence can matter.

Our pages on prostate cancer early detection and prostate cancer screening protocols explain how PSA retesting is supposed to work.

What Your Pathology Report May Have Been Telling You

Sometimes the cancer was in the sample, and the problem happened under the microscope. Reading prostate tissue takes specialized skill, and pathologists looking at the same slides don’t always agree. Two findings on a “negative” report deserve special attention.

ASAP (atypical small acinar proliferation). The pathologist saw suspicious cells but couldn’t confidently call them cancer. That isn’t a clean result. Published studies report cancer on repeat biopsy in roughly 25% to 50% of men with ASAP, and many urologists recommend a repeat biopsy or MRI within months. A report that says ASAP, followed by “come back in a year,” deserves a hard look.

HGPIN (high-grade prostatic intraepithelial neoplasia). These are abnormal-looking cells that aren’t invasive cancer. HGPIN was once treated as a strong warning sign. Its significance has been downgraded as biopsies started taking more cores, though doctors still weigh it, especially when it appears in several areas.

You can ask for your original biopsy slides to be reviewed by a different pathologist, ideally at an academic center with a dedicated genitourinary pathology service.

It’s a common, reasonable request, and it can show whether cancer was already present the first time. Labs keep slides only for a limited period, so don’t wait to ask.

Does the Delay Change Your Prognosis?

The American Cancer Society reports five-year relative survival above 99% for prostate cancer that is localized or has spread only to nearby areas, compared with 38% once it reaches distant parts of the body.

Stage is only part of the picture, though. A delay can also let a low-grade cancer become a higher-grade one, measured by Gleason score or Grade Group. That can turn a man who might have been a candidate for active surveillance or surgery alone into one who needs radiation, hormone therapy, or both, with heavier side effects. A rise in grade between the first and later biopsy can help show the disease progressed during the delay.

Not every delay changes the outcome. Some prostate cancers grow slowly, and a few months may make no real difference. Showing that the delay mattered is the job of urology and oncology experts.

When a Missed Prostate Cancer Becomes Malpractice in New York

A New York malpractice claim requires two things.

First, a provider departed from accepted standards of care.

Second, the departure was a substantial factor in causing harm. A mistake with no consequence isn’t enough, and neither is a bad outcome with no mistake.

Causation is usually the harder half. Courts look at whether the departure meaningfully reduced the patient’s chance of a better outcome, and there’s no fixed percentage.

Expert testimony is essential. A complaint must also be filed with a certificate of merit confirming the attorney consulted a physician who supports the claim.

New York’s Filing Deadline

Under CPLR 214-a, as amended by Lavern’s Law, a claim for negligent failure to diagnose cancer generally must be filed within two years and six months. The clock runs from the later of two dates:

• When you knew or reasonably should have known of the error and the harm it caused

• The end of continuous treatment for the same condition with the same provider

There is an outer limit of seven years from the negligent act or omission. For a man diagnosed years after a negative biopsy, that outer limit can be the deadline that matters most.

Claims against public hospitals, including NYC Health + Hospitals, require a notice of claim within 90 days. If a loved one has died, a wrongful death claim generally must be filed within two years of the date of death. Don’t assume you have plenty of time, and don’t assume you’re too late.

Evidence to Gather Now

Public Health Law § 18 gives you the right to your records. The most useful are:

• Your full PSA history, with dates and values

• MRI reports and the actual images on disc

• The biopsy procedure note, showing how many cores were taken and from where

• Every pathology report, including any mention of ASAP or HGPIN

• Urology notes showing what follow-up was recommended

• Portal messages, call logs, and appointment records

Request the biopsy slides for a second review as well. Then write your own timeline: when you were tested, what you were told, and when. An account written early is usually more reliable than one pieced together years later.

Talk With a New York Cancer Lawyer

If a negative biopsy was followed by a cancer diagnosis, and you suspect a rising PSA, a warning finding, or a lost result was ignored along the way, it’s worth finding out whether the delay was avoidable.

Our New York cancer lawyers work with urology and pathology experts who can tell whether a missed diagnosis reflects a real departure from the standard of care or an unavoidable limit of the test.

For more, see our prostate cancer malpractice overview and our results in delayed cancer diagnosis cases.

Call 833-888-LATE, email info@porterlawteam.com, or request a free case evaluation.

Attorney advertising. This article provides general information and is not legal or medical advice. Prior results do not guarantee a similar outcome. Filing deadlines depend on the facts of each case.

Frequently Asked Questions

Can a prostate biopsy be negative and you still have cancer?

Yes. A standard biopsy samples only about 12 cores from the gland, so a needle can pass beside a tumor without catching it, especially at the front, apex, or transition zone. In the PRECISION trial, standard biopsy found significant cancer in 26% of men, compared with 38% for MRI-targeted biopsy. A negative result lowers the risk but doesn’t rule cancer out.

What does ASAP mean on a prostate biopsy report?

ASAP stands for atypical small acinar proliferation. It means the pathologist saw suspicious cells but couldn’t confidently call them cancer. It isn’t a clean result. Published studies report cancer on repeat biopsy in roughly a quarter to half of men with ASAP, so many urologists recommend a repeat biopsy or MRI within months.

What should happen after a negative prostate biopsy if PSA keeps rising?

A rising PSA after a negative biopsy shouldn’t be ignored. Guidelines support further evaluation: repeat PSA testing, a prostate MRI to look for areas the first biopsy missed, a targeted biopsy if MRI finds a lesion, biomarker tests, or a repeat biopsy. Ask your urologist to put the follow-up plan, and who schedules it, in writing.

Can I get a second opinion on my prostate biopsy slides?

Yes. You can ask the lab or your urologist to send the original slides to another pathologist, ideally at an academic center with genitourinary pathology specialists. It’s a common request, and it can show whether cancer was present on the first biopsy. Labs keep slides only for a limited period, so ask promptly.

Can I sue if my prostate cancer was missed after a negative biopsy in New York?

Possibly. A missed tumor alone usually isn’t malpractice, but a claim may exist if a doctor ignored a rising PSA, didn’t act on ASAP or a suspicious MRI, a pathologist misread the slides, or a result was never reported. Under CPLR 214-a, these claims generally must be filed within two and a half years of discovery, with a seven-year outer limit.